-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bevacizumab is a recombinant humanized monoclonal antibody that specifically targets and binds to human vascular endothelial growth factor (VEGF), inhibits the binding of VEGF to its receptor, inhibits tumor angiogenesis, and reduces tumor blood flow.
Bevacizumab is a recombinant humanized monoclonal antibody that specifically targets and binds to human vascular endothelial growth factor (VEGF), inhibits the binding of VEGF to its receptor, inhibits tumor angiogenesis, and reduces tumor blood flow.
1.
1.
-
Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
-
Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer
Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
Indications for domestic medical insurance : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
Domestic Medical Insurance Indication Domestic Medical Insurance Indication : MetastaticColorectal cancer , non-small cell lung cancer , hepatocellular carcinoma, and recurrent glioblastoma
Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer
Indications for domestic instructions : including four medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, and refractory, recurrent or metastatic cervical cancer
Domestic label indications Domestic label indications : including four major medical insurance indications and recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer, refractory, recurrent or metastatic cervical cancer
Figure 2 Treatment steps for patients taking antihypertensive drugs for the first time (source reference [1] [1] ) (2) The question of whether bevacizumab can be used for cancer maintenance therapy .
(2) Questions about whether bevacizumab can be used for cancer maintenance therapy .
Clinical studies have shown that maintenance therapy with bevacizumab alone or in combination with other chemotherapy drugs can effectively improve PFS and OS in advanced non-small cell lung cancer, advanced ovarian cancer , metastatic colorectal cancer, advanced breast cancer, etc.
It is recommended that clinicians fully Weigh the patient's clinical benefits, adverse reactions, quality of life and economic situation, and adjust the treatment plan in a timely manner according to the principle of individualization .
Quality of life in ovarian cancer (3) Concerning the safety of minor surgery during bevacizumab administration .
(3) Concerning the safety of minor surgery during bevacizumab administration .
Foreign studies have shown that if minor surgery (including central venous catheterization/catheter removal, thoracic drainage, oral surgery, biopsy, etc.
) is required during bevacizumab administration, 16-17 days of drug withdrawal may be required before surgery Transition, if bevacizumab treatment is continued after surgery, a 9-14 day surgical recovery period is required .
References: [1] Tang Xinying, Kuang Zemin.
Expert consensus on blood pressure management in ovarian and cervical cancer patients treated with bevacizumab : Interpretation of British expert recommendations in 2019.
Rational Drug Use in China, 2020; 1: 11-15.
Consensus interpret
leave a message here